BIOTECH GROWTH TRUST (THE) ORD GBP0.25

Symbol: BIOG

Streaming is not available when market closed. Some prices may be as at close of business from the previous working day.

Whilst we endeavour to price investments on a real-time streaming or 15 min delayed basis, some prices may be as at close of business from the previous working day.

Invest in this share within an ISA, JISA, SIPP or Investment Account

Past Performance

  • 13th Nov 2014 to 13th Nov 201510.99%
  • 13th Nov 2015 to 13th Nov 20161.97%
  • 13th Nov 2016 to 13th Nov 201710.45%
  • 13th Nov 2017 to 13th Nov 2018-10.83%
  • 13th Nov 2018 to 13th Nov 20194.86%

Key Information

Benchmark Nasdaq Biotechnology
Sector IT Biotechnology & Healthcare
AMC 0.65%
Total Ongoing Charges 
Please note that whilst we endeavour to show all charges associated with specific funds, sometimes this is not possible due to the information not being made available by the fund provider. In such cases transaction or incidental cost information may be missing.
1.58%
Gearing 107%
Performance Fee No
Ex-Dividend Date Unknown
Dividend Pay Date Unknown
Total Dividends - Year to Date0
Dividend Yield (%)0

Net Asset Value (Nav)

Latest actual NAV 831.93
Latest actual NAV date 8/11/2019
NAV frequency Daily
Premium/Discount -11.77%

Cost and Charges Information

This calculator provides you with costs and charges information regarding our charges and, where relevant, the costs within this investment product

Account Type

  • Investment Account
  • Stocks & Shares ISA
  • SIPP

Annual charges

These are the annual costs based on an initial investment amount of over 1 year assuming a net zero growth rate

Cost Category % of Investment lump sum costs
Our annual fee

Our annual fee

Includes our platform fee at 0.35% per annum for Funds (up to £250,000) and Stocks & Shares (min £24 max £240), plus SIPP administration fee (if applicable, only charged if <£30,000 held) - see here
0.35%
Dealing charges

Dealing charges

Any one-off commission charges associated with investing. Note that government taxes and levies are not included
N/A
Product provider costs

Product provider costs

Product provider costs shown are inclusive of the fund ongoing charges figure (OCF), transaction costs and incidental costs
1.58%
Total (£)

Total (£)

Costs per annum displayed in monetary value
Total (%)

Total (%)

Costs per annum displayed as a percentage of investment value

Cumulative effect of charges on your investment's return

This illustration assumes that costs occur evenly throughout the year, charges are paid out of the investment evenly throughout the year, and that an annual growth rate of applies evenly throughout the year, before any charges including product charges

lump sum invested with an assumed growth rate of 1 year years
What you might get back at  with no charges applied

What you might get back at  with no charges applied

These are the illustrative values of a  investment after growth and no costs applied at the end of the defined period
Annual charges

Annual charges

These are the annual costs based on an initial investment amount of assuming a net zero growth rate
Effect of charges on return (%)

Effect of charges on return (%)

These are the overall costs in percentage terms, based on an initial investment amount of assuming a growth rate
Effect of charges on return (£)

Effect of charges on return (£)

These are the overall costs in monetary value, based on an initial investment amount of assuming a growth rate
What you might get back at with charges applied

What you might get back at with charges applied

These are the illustrative values of a investment after growth and costs at the end of the defined period

This illustration is not a forecast of future investment performance but merely a means to demonstrate the potential impact of costs and charges for an assumed return of . Whilst we make reasonable endeavours to ensure the accuracy of third party charges information, this is intended for illustrative purposes only and should not be relied upon. We do not warrant or represent that this information is accurate, complete or up to date, therefore we accept no responsibility or liability for its use

Company

Business Summary

The Biotech Growth Trust PLC is an investment trust. The Company's investment objective is to seek capital appreciation through investment in the biotechnology industry across the world. It invests in a diversified portfolio of shares and related securities in biotechnology companies. The Company will not invest more than 15%, in aggregate, of the value of its gross assets in other closed ended investment companies (including investment trusts) listed on the London Stock Exchange. The Company will not invest more than 15% of the value of its gross assets in any one individual stock at the time of acquisition. The Company will not invest more than 10% of the value of its gross assets in direct unquoted investments at the time of acquisition. OrbiMed Capital LLC is its portfolio manager. Frostrow Capital LLP is its alternative investment fund manager.

Financial Summary

BRIEF: For the fiscal year ended 31 March 2019, The Biotech Growth Trust Plc revenues increased from -£24.1M to £26.7M. Net income totaled £21.1M vs. loss of £29.8M. Revenues reflect (Losses)/gains on investments held at increase from -£28.5M to £27.8M. Net Income reflects Other costs decrease of 45% to £159K (expense), Legal and professional fees decrease of 67% to £18K (expense), Other administrative Expenses decrease of 15% to £187K (expense).

Performance

  • Chart Options

    Select Timeframe Add a sector as a comparator Add an index as a comparator Add a share as a comparator

      Add a moving average as a comparator Add a lower indicator as a comparator Chart Style Current Comparators

      Cumulative Performance

      1 month3 months6 months1 year3 years5 years
      7.94% -5.17% 7.94% 4.86% 3.27% 16.88%

      Important Information
      Headline performance can mask the true characteristics of a fund. Without fully understanding how a fund is managed, you may inadvertently become exposed to an undesirable level of risk to your capital. Some funds carry a dilution levy which reduces the number of units realised on any initial investment as an initial charge. If this fund carries such a levy it should be detailed in the Key Investor Information Document (KIID), which we must provide and you should read before investing.

      The charts and performance data shown are supplied by an external data provider and may contain data that appears to precede the introduction of the clean unit class for this fund. In such cases, historical data has been synthesised at the entire discretion of that external provider as realistically as possible using historical data recorded against the previously available commission-paying version of the fund, adjusting for fees in the process.

      Composition

      Important Documents


      The documents listed below are the latest versions made available to our data provider by the fund management group, but may not necessarily reflect the applicable charges that would be levied should you purchase this fund via Charles Stanley Direct. You should treat the charges and other figures shown in the 'Overview' tab as accurate.

      Fund Provider Factsheet
      The Fact Sheet is supplied on a monthly basis by the management group and provides limited information on the fund. Past performance data and a review of how the fund has performed are commonly featured.
      FUND PROVIDER FACTSHEET
      298,526 bytes PDF Document; last updated 30 Sep 2019
      Key Information Document This document, issued by the product provider, provides key information about an investment product. The information is required by law to help potential investors understand the nature, risks, costs, potential gains and losses of the product and enable comparison with other products.
      KEY INFORMATION DOCUMENT
      63,842 bytes PDF Document; last updated 19 Sep 2019
      Annual Report A report published by the Fund Management Group detailing the progress of the fund during the course of the previous 12 months. The information provided includes a financial statement for the group as a whole.
      ANNUAL REPORT
      779,186 bytes PDF Document; last updated 31 Mar 2019
      Semi Annual Report Published periodically through the course of the financial year of the fund, the report provides an overview of the fund's performance and the prospects for the remainder of the year. Included are portfolio changes (i.e. which stocks have been bought and sold), and changes in the geographical breakdown during the course of the previous 12 months.
      SEMI-ANNUAL REPORT
      392,435 bytes PDF Document; last updated 30 Sep 2018

      Management Team

      Richard D Klemm Geoffrey C. Hsu Orbimed Capital

      Richard D Klemm has managed this fund for 14 years and 5 months.

      Richard D Klemm Richard D. Klemm, Ph.D., CFA, joined OrbiMed in 2000 as a public biotechnology company analyst. He completed a Ph.D. from the Massachusetts Institute of Technology in molecular biology in 2000. Dr. Klemm has published scientific articles in the fields of DNA replication and transcription. He received a B.A. from the University of California, Berkeley in 1994 with majors in molecular and cell biology and economics.

      Manager Cumulative Performance v Peer Group

      Performance Graph

      Geoffrey C. Hsu has managed this fund for 14 years and 5 months.

      Geoffrey C. Hsu Geoffrey C. Hsu, CFA, is a General Partner of OrbiMed, having joined in 2002 as a public biotechnology analyst. Prior to joining OrbiMed, he worked as a financial analyst in the healthcare investment banking group at Lehman Brothers. Mr. Hsu received his A.B. degree summa cum laude from Harvard University and holds an M.B.A. from Harvard Business School. Prior to business school, he spent two years studying medicine at Harvard Medical School.

      Manager Cumulative Performance v Peer Group

      Performance Graph

      Orbimed Capital There is currently no biography information for Orbimed Capital .

      Manager Cumulative Performance v Peer Group

      Performance Graph

      Financials


      Income Statement - All values are in GBP (M).

      Year Ending

      31/03/2019

      31/03/2018

      31/03/2017

      31/03/2016

      31/03/2015

      31/03/2014

      Total Revenue 26.66 -24.09 103.47 -125.27 221.15 90.16
      Gross profit 21.83 -28.80 99.28 -127.96 215.13 87.30
      Operating Profit/Loss 21.29 -29.54 98.58 -128.70 214.39 86.43
      Profit Before Tax 21.29 -29.54 98.58 -128.70 214.39 86.43
      Profit After Tax 21.10 -29.78 98.30 -128.95 214.26 86.34
      Equity Holders of Parent Company 21.10 -29.78 98.30 -128.95 214.26 86.34
      Minority Interest NIL NIL NIL NIL NIL NIL


      Balance Sheet - All values are in GBP (M).

      Year Ending

      31/03/2019

      31/03/2018

      31/03/2017

      31/03/2016

      31/03/2015

      31/03/2014

      Total Non-Current Assets 431.17 445.67 461.38 420.43 583.21 368.36
      Total Current Assets 0.06 0.41 0.12 4.72 3.33 12.07
      Total Assets 431.23 446.07 461.50 425.15 586.53 380.43
      Total Liabilities NIL NIL NIL NIL NIL NIL
      Total Net Assets NIL NIL NIL NIL NIL NIL
      Shareholders Funds 408.88 417.40 447.18 378.57 533.30 340.25
      Minority Interests NIL NIL NIL NIL NIL NIL
      Total Equity NIL NIL NIL NIL NIL NIL

      Investment involves risk. You may get back less than invested.